Skip to main content
Y-Biologics, Inc logo

Y-Biologics, Inc — Investor Relations & Filings

Ticker · 338840 ISIN · KR7338840002 KO Professional, scientific and technical activities
Open in API
Filings indexed 117 across all filing types
Latest filing 2023-11-03 Capital/Financing Update
Country KR South Korea
Listing KO 338840

About Y-Biologics, Inc

https://ybiologics.com/en/

Y-Biologics, Inc. is a biotechnology company specializing in the discovery and development of novel antibody-based therapeutics. The company's primary focus is on immuno-oncology, where it develops next-generation multispecific antibodies for the treatment of cancer. Y-Biologics leverages its proprietary human antibody discovery platform to advance its internal pipeline and support collaborations through technology transfers and joint development partnerships.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서(지분증권)' (Securities Registration Statement for Equity Securities) filed with the Financial Supervisory Service (FSS) in South Korea. It explicitly mentions '정정신고' (Amendment Filing) and details the history of amendments to the original registration statement. This document is a formal regulatory filing required for public offerings or capital changes, which falls under the category of 'Regulatory Filings' (RNS) as it is a specific legal filing document that does not fit into the other specialized categories like 10-K or Earnings Release.
2023-11-03 Korean
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment (정정신고) filed by Y-Biologics. It details specific corrections and additions to the original registration statement, including risk factors, business descriptions, and financial data. In the context of Korean financial filings, a 'Securities Registration Statement' (증권신고서) is a regulatory document filed for public offerings or capital changes. Since it is a formal regulatory filing for a capital-related event, it falls under the 'Regulatory Filings' category as the most appropriate classification for this type of official disclosure.
2023-10-23 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Y-Biologics, covering the period from January 1, 2023, to September 30, 2023. It contains detailed corporate information, history, capital structure, and financial data, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-10-20 Korean
증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission (FSC) in South Korea. It details the company's business, financial risks, and the terms of a public offering of shares (1,500,000 common shares). This is a formal regulatory filing required for companies planning to list on the KOSDAQ market or raise capital through public offerings. Among the provided categories, this fits best as a 'Regulatory Filing' (RNS) as it is a formal legal document submitted to a regulatory body for public disclosure, and it does not fit the specific definitions of an Annual Report, Earnings Release, or other specialized categories.
2023-10-05 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Y-Biologics Inc., covering the period from January 1, 2023, to June 30, 2023. It contains detailed corporate information, financial data, capital changes, and governance details, which are characteristic of a comprehensive interim financial report. It is not an announcement of a report, but the report itself. H1 2023
2023-08-14 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Y-Biologics Inc., covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial and operational information, including company overview, history, capital changes, and business descriptions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-12 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.